Impact of Cannabis on Opioid Self-Administration
Shanna Babalonis, PhD
Summary
The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can alter the drive/desire to take opioids.
Eligibility
- Age range
- 18–55 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participants with moderate to severe opioid use disorder who experience opioid withdrawal * No allergies or adverse reactions to cannabis or opioids * Willing to stay inpatient at the UK Hospital research center for approx. 6 weeks Exclusion Criteria: * Individuals seeking treatment for opioid use disorder
Interventions
- DrugCannabis
Cannabis is administered three times daily during the active cannabis treatment period.
- DrugPlacebo Cannabis
Matched placebo cannabis is administered three times daily during the placebo treatment period.
- DrugIntranasal Opioid Agonist
Intranasal opioid agonists are administered during sample and self-administration sessions
- DrugOral Opioid Agonist
Oral opioid agonist maintenance doses are administered four times daily throughout study participation.
Location
- University of Kentucky Center on Drug and Alcohol ResearchLexington, Kentucky